M. Sepandi, A. Rezaianzadeh, S. Afrashteh, Y. Alimohamadi, Abbas Abbasi-Ghahramanaloo
Aim: This study aimed to find subgroups of women on the basis of clustering of breast cancer risk factors. Materials & methods: The study was conducted in Shiraz between 2004 and 2013. In this cross-sectional study clinical breast examination, mammography or sonography, fine needle aspiration or biopsy and surgery in case of indications were performed for all participants. Results: Four latent classes were indentified among women with breast cancer; general population risk (65.7%), low risk (8.9%), moderate risk (20.5%) and high risk (4.9%). Conclusion: Focusing on education, age and the occupation of women may help in designing and executing effective programs to reduce the incidence of breast cancer among healthy women.
{"title":"The pattern of breast cancer risk factors among Iranian women and predictors of class membership","authors":"M. Sepandi, A. Rezaianzadeh, S. Afrashteh, Y. Alimohamadi, Abbas Abbasi-Ghahramanaloo","doi":"10.2217/bmt-2023-0006","DOIUrl":"https://doi.org/10.2217/bmt-2023-0006","url":null,"abstract":"Aim: This study aimed to find subgroups of women on the basis of clustering of breast cancer risk factors. Materials & methods: The study was conducted in Shiraz between 2004 and 2013. In this cross-sectional study clinical breast examination, mammography or sonography, fine needle aspiration or biopsy and surgery in case of indications were performed for all participants. Results: Four latent classes were indentified among women with breast cancer; general population risk (65.7%), low risk (8.9%), moderate risk (20.5%) and high risk (4.9%). Conclusion: Focusing on education, age and the occupation of women may help in designing and executing effective programs to reduce the incidence of breast cancer among healthy women.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":"1 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48751885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Perrone, Melania Dovizio, Melania Leogrande, Antonella Tamma, M. Giovannitti, Carlotta Buzzoni, L. Esposti
Aim: Italian real-world analysis of CDK4/6 inhibitor (CDK4/6i) treatment in HR+/HER2- metastatic breast cancer aimed at evaluating patients' medical history, treatment duration, treatment patterns (combination with endocrine therapy), line of therapy and drug dose variations. Materials & methods: CDK4/6i treatment was analyzed using healthcare administrative databases covering 18% of Italians between January 2017 and June 2022. Results: Among CDK4/6i-treated women, palbociclib and abemaciclib (were more frequently combined with fulvestrant, while ribociclib with aromatase inhibitors. CDK4/6i recommended doses were initiated in 72–90% patients and maintained after 3–6 months in respectively 65–57% women. Frontline CDK4/6i use grew over time (reaching 90%). Median time-to-treatment discontinuation was 11.0 months in palbociclib, 15.9 in abemaciclib and 15.4 in ribociclib cohorts. Conclusion: CDK4/6i plus endocrine therapy is increasingly utilized as first-line therapy, with low proportions of dose reductions within 6 months and discontinuations at 1 year.
{"title":"Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy","authors":"V. Perrone, Melania Dovizio, Melania Leogrande, Antonella Tamma, M. Giovannitti, Carlotta Buzzoni, L. Esposti","doi":"10.2217/bmt-2023-0020","DOIUrl":"https://doi.org/10.2217/bmt-2023-0020","url":null,"abstract":"Aim: Italian real-world analysis of CDK4/6 inhibitor (CDK4/6i) treatment in HR+/HER2- metastatic breast cancer aimed at evaluating patients' medical history, treatment duration, treatment patterns (combination with endocrine therapy), line of therapy and drug dose variations. Materials & methods: CDK4/6i treatment was analyzed using healthcare administrative databases covering 18% of Italians between January 2017 and June 2022. Results: Among CDK4/6i-treated women, palbociclib and abemaciclib (were more frequently combined with fulvestrant, while ribociclib with aromatase inhibitors. CDK4/6i recommended doses were initiated in 72–90% patients and maintained after 3–6 months in respectively 65–57% women. Frontline CDK4/6i use grew over time (reaching 90%). Median time-to-treatment discontinuation was 11.0 months in palbociclib, 15.9 in abemaciclib and 15.4 in ribociclib cohorts. Conclusion: CDK4/6i plus endocrine therapy is increasingly utilized as first-line therapy, with low proportions of dose reductions within 6 months and discontinuations at 1 year.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":"21 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139371231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mahdiss Mohamadianamiri, A. Ebrahimi, F. Farzaneh, Majid Aklami, Mina Momeni, Tannaz Hajighasem, Hossein Shirazi, Mohammadreza Zeinadini
Background: Triple-negative breast cancer (TNBC) is associated with a poor prognosis and requires more aggressive treatment. Aim: The study aimed to evaluate the prophetic role of the prolactin receptor (PRLR) in TNBC stratification. Materials & methods: In a retrospective study, 58 formalin-fixed paraffin-embedded tumor tissues from patients diagnosed with TNBC were examined for PRLR expression using immunohistochemistry. The potential associations between PRLR expression and tumor characteristics were assessed. Result: PRLR expression was negative in 36 (62%) patients and positive in 22 (38%) patients. The number of positive PRLR tumors was significantly higher in patients without lymph node involvement (p = 0.019). Conclusion: PRLR expression was negatively associated with lymph node invasion in TNBC.
{"title":"The association between expression of prolactin receptor and lymph node involvement in triple-negative breast cancer","authors":"Mahdiss Mohamadianamiri, A. Ebrahimi, F. Farzaneh, Majid Aklami, Mina Momeni, Tannaz Hajighasem, Hossein Shirazi, Mohammadreza Zeinadini","doi":"10.2217/bmt-2022-0006","DOIUrl":"https://doi.org/10.2217/bmt-2022-0006","url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) is associated with a poor prognosis and requires more aggressive treatment. Aim: The study aimed to evaluate the prophetic role of the prolactin receptor (PRLR) in TNBC stratification. Materials & methods: In a retrospective study, 58 formalin-fixed paraffin-embedded tumor tissues from patients diagnosed with TNBC were examined for PRLR expression using immunohistochemistry. The potential associations between PRLR expression and tumor characteristics were assessed. Result: PRLR expression was negative in 36 (62%) patients and positive in 22 (38%) patients. The number of positive PRLR tumors was significantly higher in patients without lymph node involvement (p = 0.019). Conclusion: PRLR expression was negatively associated with lymph node invasion in TNBC.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":"1 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43203700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guolian Zheng, Haoyang Wang, Fang-Yu Liu, J. P. Leone
Aim: Male breast cancer (MBC) is a rare disease and accounts for approximately 1% of breast cancer. Treatment is largely extrapolated from female breast cancer due to lack of data in MBC. However, there are distinct features of MBC that warrant different treatment approach. We aim to better characterize the risk factors, clinicopathologic features, treatment and outcome of MBC patients from six hospitals across Steward Healthcare Network. Materials & methods: A total of 107 men with breast cancer were identified from the respective cancer registry at Steward and 64 patients were included with complete medical records. Their clinical, histopathological and treatment records were retrospectively reviewed. Kaplan–Meier method was used to determine the 5, 10 year overall survival (OS) rate and relapse free survival rate and Cox Regression test was used to assess the association between patient outcome and age at diagnosis, metastasis status at time of diagnosis, tumor size, nodal involvement and use of chemotherapy. Results: Of these 64 patients, median age at diagnosis was 68 years, majority of patients were white, 13 patients had family history of breast or ovarian cancer (20.3%), four patients tested positive for BRCA2 (6.25). Majority of patients presented painless breast lump. A total of 59 patients (92.2%) had invasive ductal carcinoma, and 31 patients (48.4%) had lymph node involvement at time of diagnosis. A total of 62 patients (96.8%) had M0 disease at time of diagnosis. About 97% of patients had estrogen receptor (ER) positive cancer. Most patients underwent mastectomy (87.5%), 35 patients (54.6%) received adjuvant radiation therapy, 19 patients (30%) received adjuvant chemotherapy and 96.7% of patients received adjuvant hormonal therapy. The median follow-up was 71.5 months (range 6–250 months), 5-year survival rate was 86.9% (95% CI: 74.5–93.6%), 5-year relapse free survival rate was 89.9% (95% CI: 77.4–95.7%) and 10-year survival rate was 58.1% (95% CI: 41.0–71.8%). The presence of distant metastasis at the time of initial diagnosis was the only factor associated with shorter OS (hazard ratio: 22.54, p < 0.0001). Conclusion: Majority of MBC patients present with palpable breast mass and the tumors are almost exclusively hormone receptor positive. Majority of patients present without distant metastasis and received surgical therapy; however, only a small subset of patients received breast conserving surgery for T1 tumor. Almost all patients received adjuvant hormonal therapy. OS and relapse free survival in our cohort is similar to historic reports in female breast cancer.
{"title":"Male breast cancer: a 20-year multicenter experience","authors":"Guolian Zheng, Haoyang Wang, Fang-Yu Liu, J. P. Leone","doi":"10.2217/bmt-2022-0004","DOIUrl":"https://doi.org/10.2217/bmt-2022-0004","url":null,"abstract":"Aim: Male breast cancer (MBC) is a rare disease and accounts for approximately 1% of breast cancer. Treatment is largely extrapolated from female breast cancer due to lack of data in MBC. However, there are distinct features of MBC that warrant different treatment approach. We aim to better characterize the risk factors, clinicopathologic features, treatment and outcome of MBC patients from six hospitals across Steward Healthcare Network. Materials & methods: A total of 107 men with breast cancer were identified from the respective cancer registry at Steward and 64 patients were included with complete medical records. Their clinical, histopathological and treatment records were retrospectively reviewed. Kaplan–Meier method was used to determine the 5, 10 year overall survival (OS) rate and relapse free survival rate and Cox Regression test was used to assess the association between patient outcome and age at diagnosis, metastasis status at time of diagnosis, tumor size, nodal involvement and use of chemotherapy. Results: Of these 64 patients, median age at diagnosis was 68 years, majority of patients were white, 13 patients had family history of breast or ovarian cancer (20.3%), four patients tested positive for BRCA2 (6.25). Majority of patients presented painless breast lump. A total of 59 patients (92.2%) had invasive ductal carcinoma, and 31 patients (48.4%) had lymph node involvement at time of diagnosis. A total of 62 patients (96.8%) had M0 disease at time of diagnosis. About 97% of patients had estrogen receptor (ER) positive cancer. Most patients underwent mastectomy (87.5%), 35 patients (54.6%) received adjuvant radiation therapy, 19 patients (30%) received adjuvant chemotherapy and 96.7% of patients received adjuvant hormonal therapy. The median follow-up was 71.5 months (range 6–250 months), 5-year survival rate was 86.9% (95% CI: 74.5–93.6%), 5-year relapse free survival rate was 89.9% (95% CI: 77.4–95.7%) and 10-year survival rate was 58.1% (95% CI: 41.0–71.8%). The presence of distant metastasis at the time of initial diagnosis was the only factor associated with shorter OS (hazard ratio: 22.54, p < 0.0001). Conclusion: Majority of MBC patients present with palpable breast mass and the tumors are almost exclusively hormone receptor positive. Majority of patients present without distant metastasis and received surgical therapy; however, only a small subset of patients received breast conserving surgery for T1 tumor. Almost all patients received adjuvant hormonal therapy. OS and relapse free survival in our cohort is similar to historic reports in female breast cancer.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47884134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial intelligence techniques for the diagnosis of disease continue to develop with rapid pace. This review article systematically determines incremental accuracy and other parameters of current methods, including sensitivity, specificity, positive predictive value and negative predictive value with regard to breast MRI as a screening tool for women under 50 years. Articles were included from the databases of health technology assessment agencies from 2000 to 2019, using various medical subject heading terms. A total of 23 eligible studies were included incorporating a total of 11,688 patients out of which two were multicentered, four were accuracy studies, seven were prospective studies and four were retrospective studies. MRI screening showed an adequate detection of invasive cancers, premalignant lesions and pre-invasive cancers, suggesting that MRI is a powerful surveillance tool to detect cancer in high-risk populations. These findings have indicated that MRI has particular sensitivity and specificity for the diagnosis of breast cancer. PROSPERO Registration Number: CRD42020158372.
{"title":"Effectiveness of MRI in screening women for breast cancer: a systematic review","authors":"R. Ahmad, B. Ahmed, B. Ahmed","doi":"10.2217/bmt-2021-0016","DOIUrl":"https://doi.org/10.2217/bmt-2021-0016","url":null,"abstract":"Artificial intelligence techniques for the diagnosis of disease continue to develop with rapid pace. This review article systematically determines incremental accuracy and other parameters of current methods, including sensitivity, specificity, positive predictive value and negative predictive value with regard to breast MRI as a screening tool for women under 50 years. Articles were included from the databases of health technology assessment agencies from 2000 to 2019, using various medical subject heading terms. A total of 23 eligible studies were included incorporating a total of 11,688 patients out of which two were multicentered, four were accuracy studies, seven were prospective studies and four were retrospective studies. MRI screening showed an adequate detection of invasive cancers, premalignant lesions and pre-invasive cancers, suggesting that MRI is a powerful surveillance tool to detect cancer in high-risk populations. These findings have indicated that MRI has particular sensitivity and specificity for the diagnosis of breast cancer. PROSPERO Registration Number: CRD42020158372.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44108106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Fortin, Anaïs Beaupré, Lunie Anne Thamar Louis, Carol-Anne Roy, M. A. Bourque, Sarah Cappeliez, Asma Fadhlaoui
Aim: In Canada, osteopathic medicine, a well-known branch of complementary/alternative medicine, has received minimal attention for pain management within oncology. Purpose: This review reports both the existing literature and patient experience surrounding the application of osteopathy as an effective treatment for pain in breast cancer patients. Results: Both the literature and this case study support, to some degree, the benefits of osteopathy as pain management for breast cancer patients. Conclusion: Due to contradictory reported findings, more studies would be required to make firm conclusions, especially within a Canadian context. However, a lack of standardization of osteopathic procedures and collaboration between osteopaths and traditional healthcare professionals are challenges in including osteopathy as a standard service offered to breast cancer patients.
{"title":"Osteopathy as a complementary/alternative medicine for breast cancer: a Canadian case study and comprehensive review","authors":"J. Fortin, Anaïs Beaupré, Lunie Anne Thamar Louis, Carol-Anne Roy, M. A. Bourque, Sarah Cappeliez, Asma Fadhlaoui","doi":"10.2217/bmt-2022-0002","DOIUrl":"https://doi.org/10.2217/bmt-2022-0002","url":null,"abstract":"Aim: In Canada, osteopathic medicine, a well-known branch of complementary/alternative medicine, has received minimal attention for pain management within oncology. Purpose: This review reports both the existing literature and patient experience surrounding the application of osteopathy as an effective treatment for pain in breast cancer patients. Results: Both the literature and this case study support, to some degree, the benefits of osteopathy as pain management for breast cancer patients. Conclusion: Due to contradictory reported findings, more studies would be required to make firm conclusions, especially within a Canadian context. However, a lack of standardization of osteopathic procedures and collaboration between osteopaths and traditional healthcare professionals are challenges in including osteopathy as a standard service offered to breast cancer patients.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47225916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Dastgiri, G. D. de Bock, Z. Sanaat, M. Ranjkesh, Z. Abbasi, P. Jabbaripour, Shima Pashaie, Soheila Poorsaberi, R. Dolatkhah
Aim: Breast cancer screening intended to improve survival and treatment outcomes. This study aimed to document the acceptability and compliance of the breast cancer prevention campaigns. Materials & methods: Healthy women aged 35–65 years were recruited from various regions of the Northwest of Iran. All women were invited to participate in self-examination training for the breast and then re-assessed by clinical examination and mammography. Results: A total of 321 healthy women were recruited, and volunteered to undergo at least one breast self-examination. The first and second clinical examinations were conducted on all women. Ultimately, 272 women (84.7%) underwent mammography. The most common barriers to screening were found to be fear of positive results, fear of cancer, lack of knowledge, fear of the mammography procedure and pain, travel distance and costs. Conclusion: The most critical challenge for implementing a breast cancer prevention program was the lack of knowledge and attitude.
{"title":"Acceptability and compliance with a breast cancer prevention campaign in the Northwest Region, Iran","authors":"S. Dastgiri, G. D. de Bock, Z. Sanaat, M. Ranjkesh, Z. Abbasi, P. Jabbaripour, Shima Pashaie, Soheila Poorsaberi, R. Dolatkhah","doi":"10.2217/bmt-2021-0004","DOIUrl":"https://doi.org/10.2217/bmt-2021-0004","url":null,"abstract":"Aim: Breast cancer screening intended to improve survival and treatment outcomes. This study aimed to document the acceptability and compliance of the breast cancer prevention campaigns. Materials & methods: Healthy women aged 35–65 years were recruited from various regions of the Northwest of Iran. All women were invited to participate in self-examination training for the breast and then re-assessed by clinical examination and mammography. Results: A total of 321 healthy women were recruited, and volunteered to undergo at least one breast self-examination. The first and second clinical examinations were conducted on all women. Ultimately, 272 women (84.7%) underwent mammography. The most common barriers to screening were found to be fear of positive results, fear of cancer, lack of knowledge, fear of the mammography procedure and pain, travel distance and costs. Conclusion: The most critical challenge for implementing a breast cancer prevention program was the lack of knowledge and attitude.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45979134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sanura Malinda Pallegoda Vithana, L. Chathuranga, S. Jayasinghe, Edippuli Arachchige Don Udayakumara
Male breast cancers account for 1% of worldwide breast malignancies and are on the rise. Sri Lankan accounts are limited due to lack of healthcare seeking behavior among men. A 63-year-old male presented with a right sided hard breast lump and a Breast Imaging Reporting and Database System score 5 lesion with axillary lymph node metastasis was observed on ultrasonography. Core biopsy revealed invasive ductal breast cancer. Tumor staging revealed a T2N1M0 cancer for which mastectomy with level 2 axillary clearance was performed followed by radiotherapy and systemic therapy. Male breast cancer even though similar to female breast cancers have important distinctions with regard to molecular biology, lymphatic metastasis and age of presentation. Management; however, still relies on studies based on the female counterpart.
{"title":"Male breast cancer: a Sri Lankan case report and review of literature","authors":"Sanura Malinda Pallegoda Vithana, L. Chathuranga, S. Jayasinghe, Edippuli Arachchige Don Udayakumara","doi":"10.2217/bmt-2021-0014","DOIUrl":"https://doi.org/10.2217/bmt-2021-0014","url":null,"abstract":"Male breast cancers account for 1% of worldwide breast malignancies and are on the rise. Sri Lankan accounts are limited due to lack of healthcare seeking behavior among men. A 63-year-old male presented with a right sided hard breast lump and a Breast Imaging Reporting and Database System score 5 lesion with axillary lymph node metastasis was observed on ultrasonography. Core biopsy revealed invasive ductal breast cancer. Tumor staging revealed a T2N1M0 cancer for which mastectomy with level 2 axillary clearance was performed followed by radiotherapy and systemic therapy. Male breast cancer even though similar to female breast cancers have important distinctions with regard to molecular biology, lymphatic metastasis and age of presentation. Management; however, still relies on studies based on the female counterpart.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43752331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Canino, L. Moscetti, V. Borghi, M. Dominici, F. Piacentini
The use of drugs that affect the cell cycle represents one of the common strategies for the control of some unrelated pathologies, such as chronic viral HIV infections or cancer. The authors report the case of a patient followed for a hormone receptor-positive (HR+)/HER2 negative (HER2-) advanced breast cancer, treated with hormone therapy and CDK 4/6 inhibitors, and a concomitant HIV infection under antiretroviral treatment. The authors consider the function of the sterile alpha motif and HD domain-containing protein-1 (SAMHD1) enzyme, its implications in the control of viral replication and the correlation between its activity and the mechanism of action of the CDK 4/6 inhibitor palbociclib.
{"title":"Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: a case report","authors":"F. Canino, L. Moscetti, V. Borghi, M. Dominici, F. Piacentini","doi":"10.2217/bmt-2021-0006","DOIUrl":"https://doi.org/10.2217/bmt-2021-0006","url":null,"abstract":"The use of drugs that affect the cell cycle represents one of the common strategies for the control of some unrelated pathologies, such as chronic viral HIV infections or cancer. The authors report the case of a patient followed for a hormone receptor-positive (HR+)/HER2 negative (HER2-) advanced breast cancer, treated with hormone therapy and CDK 4/6 inhibitors, and a concomitant HIV infection under antiretroviral treatment. The authors consider the function of the sterile alpha motif and HD domain-containing protein-1 (SAMHD1) enzyme, its implications in the control of viral replication and the correlation between its activity and the mechanism of action of the CDK 4/6 inhibitor palbociclib.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41468182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Yadav, Karthik V. Giridhar, J. P. Leone, R. Leon-Ferre, K. Ruddy
The majority (more than 90%) of male breast cancers (MaBCs) are estrogen receptor-positive, such that endocrine therapy is the mainstay of MaBC treatment. Endocrine therapy has been associated with improved overall survival in observational studies on MaBC, though large randomized clinical trials have never been completed to confirm this benefit in this population. Tamoxifen is currently the preferred drug for both metastatic and adjuvant treatment of MaBC. Known differences in treatment patterns and hormonal milieu between men and women may warrant a unique approach to the management of toxicities in men. This review provides a detailed discussion of endocrine therapy for MaBC.
{"title":"A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer","authors":"S. Yadav, Karthik V. Giridhar, J. P. Leone, R. Leon-Ferre, K. Ruddy","doi":"10.2217/bmt-2021-0001","DOIUrl":"https://doi.org/10.2217/bmt-2021-0001","url":null,"abstract":"The majority (more than 90%) of male breast cancers (MaBCs) are estrogen receptor-positive, such that endocrine therapy is the mainstay of MaBC treatment. Endocrine therapy has been associated with improved overall survival in observational studies on MaBC, though large randomized clinical trials have never been completed to confirm this benefit in this population. Tamoxifen is currently the preferred drug for both metastatic and adjuvant treatment of MaBC. Known differences in treatment patterns and hormonal milieu between men and women may warrant a unique approach to the management of toxicities in men. This review provides a detailed discussion of endocrine therapy for MaBC.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41769928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：